Who We Are


Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), is an innovation driven, fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products and diagnostics. Globally, the group has a strong presence in 50 countries worldwide including the regulated markets of the US, Europe and the Latin America and other emerging markets.

With several innovations to its credit, the group launched Exemptia, the world’s first biosimilar of Adalimumab, the largest selling therapy worldwide for inflammatory arthritis. Zydus is also the only Indian pharma company to launch its own patented NCE – Lipaglyn, the novel drug approved for the treatment of diabetic dyslipidemia. The group’s NCE Saroglitazar is the first drug to be approved anywhere in the world for NASH (Non-Alcoholic Steato Hepatitis), an unmet healthcare need. Twinrab, the group’s novel biologic developed in collaboration with the WHO is a next generation anti-rabies therapy for rabies post-exposure prophylaxis. The drug has been given an orphan drug status by the USFDA.

The group’s origin can be traced to 1952 when it was founded by Late Mr. Ramanbhai B. Patel, a first-generation entrepreneur and one of the stalwarts of the Indian Pharmaceutical Industry. In 1995, the group restructured its operations and Cadila Healthcare came into being under the aegis of the Zydus group. From a turnover of INR. 250 crores in 1995, the group posted revenues of over INR. 15,000 crores in FY 21.

The Zydus group bagged the India Pharma Overall Excellence Award and India Pharma Innovation of the Year Award from the Govt. of India. The group also won the CII Industrial Innovation Grand Jury Award of being the Most Innovative Company of the Year and declared the most Innovative Pharmaceutical Company by Thomson Reuters. The Zydus group was amongst the top 3 finalists at the Time India Awards 2017 in the ‘Global Manufacturer for the Year’ category and ranked amongst the top five companies worldwide at the FT ArcelorMittal Boldness in Business Awards 2014 in the Developing Markets category.

Supporting its marketing prowess is the group’s manufacturing facilities. The group has state-of-the-art vertically integrated manufacturing facilities for APIs and formulations, spread across Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India, besides plants in Myanmar, Brazil and USA.

The group has a team of over 1400 research professionals spearheading its research and development programme of which nearly 400 scientists alone are involved in the NME research programme at Zydus Research Centre, the group’s state-of-the-art R&D centre. Within a short span of time, the group has made remarkable progress on the New Molecular Entity (NME) research and has several candidates in various stages of clinical development.

Zydus with a mission to create healthier, happier communities globally, is supported by a team of over 25,000 people worldwide, comprising professionals, research scientists, medical advisors and workers.

This information is intended for Healthcare Professionals in Sri Lanka only

Would you like to continue?

Yes No